WORCESTER, Mass., July 10, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has entered into an exclusive Product Licensing & Distribution Agreement with the Armenian Development Agency (ADA) (http://www.ada.am) and Canada Armenia Trading House Ltd. (CATH) for the commercialization of Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, in the Republic of Armenia, Georgia, and the Republic of Kazakhstan. ADA and CATH will bear any and all costs associated with the procurement of governmental approvals for the sale of the product, including any clinical and regulatory costs.
